Late relapse of epithelial ovarian cancer: A single institution experience

Purpose of investigation: Late relapses are infrequent in ovarian cancer. We present the characteristics and outcome of patients who relapsed at least five years after first-line chemotherapy.

Methods: Six cases were retrieved from 203 patients treated from 1994 to 1998.

Results: Time to recurrence ranged from five to nine years. The initial stage was I or II in all cases, while histology was: endometrioid (4 cases), clear cell (1 case) and unspecified adenocarcinoma (1 case). Only two of five assessable patients responded to chemotherapy. Compared to earlier relapses, late relapses were characterized by earlier stages (p < 0.001), non serous histology (p = 0.010) and absence of symptoms (0% vs 46.5%, p = 0.025) at baseline. Five of 16 relapses (31%) among patients with Stage I or II were late relapses.

Conclusion: Late relapses of ovarian cancer occur in early stages, where they are relatively frequent, while the chemosensitivity of the disease may be less than expected.

Ovarian cancer; Late relapse; Management

[1] Ozols R.F.: "Future directions in the treatment of ovarian cancer". Sem. Oneal., 2002, 29 (suppl. 1), 32.

[2] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Patridge E.E., Look K.Y. et al.: "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer". N. Engl. J. Med., 1996, 334, 1.

[3] Omura G.A., Brady M.F., Homesley H.D., Yordan E., Major F.G., Buchsbaum H.G. et al.: "Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience". J. Clin. Oneal., 1991, 9, 1138.

[4] Rubin S.C., Hoskins W.J., Saigo P.E., Chapman D., Hakes T.B., Markman M. et al.: "Prognostic factors for recurrence following negative second look laparotomy in ovarian cancer patients treated with platinum based chemotherapy". Gynecol. Oneal., 1991, 42, 137.

[5] Del Campo J.M., Felip E., Rubio D., Vidal R., Bermego B., Colomer R. et al.: "Long term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment". Gynecol. Oneal., 1994, 53, 27.

[6] Baker T.R., Piver M.S., Hempting R.E.: "Long term survival by cytoreductive surgery to less than I cm, induction weekly cisplatin, doxorubicin and cyclophosphamide therapy in advanced ovarian adenocarcinoma". Ann. Oneal., 1994, 4, 656.

[7] Barakat R.R., Sabbatini P., Bhaskaran D., Revsin M., Smith A., Vekatraman E. et al.: "lntraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up". J. Clin. Oneal., 2002, 20, 694.

[8] Ozols R.F., Rubin S.C., T homas G., Robboy S.: "Epithelial cancer". In: Hoskins W.J., Perez C.A., Young R.C. (eds.). Principles and Practice of Gynecologic Oncology. 2"'edition. Philadelphia, Lippincott-Raven,1997, 919.

[9] Raymond E., Drolet Y., Marpeau L., Louvet C., Cady J., Tessier C. et al.: "Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma". Eur. J. Obst. Gynecol. Rep. Biol., 1997, 72, 181.

[10] Rubin S.C., Hoskins W.J., Saigo P.E., Hakes T.B., Markman M., Cain J.M. et al.: "Recurrence after negative second-look laparotomy for ovarian cancer: Analysis of risk factors". Am. J. Obstet. Gynecol., 1988, 159, 1094.

[11] Kolomainen D.F., Larkin J.M.G., Badran M., A'Hem R.P., King D.M., Fisher C. et al.: "Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence". J. Clin. Oneal., 2002, 20, 982.

[12] Backledge G., Lawton F., Redman C.: "Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patients treatment and the design of phase II trials". Br. J Cancer, 1989, 59, 650.

[13] Markman M., Rothman R., Hakes T.: "Second-line platinum chemotherapy in patients with ovarian cancer previously treated with cisplatin". J. Clin. Oneal., 1991, 9, 389.

[14] Williams L.L., Brunetto V.L., Yordan E., Disaia P.J., Creasman W.T.: "Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: A Gynecologic Oncology Group Study". Gynecol. Oneal., 1997, 66, 171.

[15] Vascarello L., Rubin S.C., Vlamis V.: "Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response". Gynecol. Oneal., 1995, 67, 61.